Qilian International Holding Group (NasdaqGM:QLI) - Share price, News & Analysis

QLI fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

QLI Stock Overview

Risk Analysis

Earnings have declined by 3.9% per year over past 5 years

Profit margins (5.5%) are lower than last year (10.1%)

Does not have a meaningful market cap ($71M)

Qilian International Holding Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Qilian International Holding Group
Historical stock prices
Current Share Price	US$1.99
52 Week High	US$4.50
52 Week Low	US$1.36
Beta	0
1 Month Change	14.37%
3 Month Change	17.06%
1 Year Change	-54.77%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-80.10%

Recent News & Updates

Sep 23

We Think You Can Look Beyond Qilian International Holding Group's (NASDAQ:QLI) Lackluster Earnings

Shareholders appeared unconcerned with Qilian International Holding Group Limited's ( NASDAQ:QLI ) lackluster earnings...

May 05

Qilian International signs Gan Di Xin's exclusive distribution agreement

Qilian International Holding Group ([[QLI]] +2.0%) announces agency agreement with China's Henan Kangzhiyuan Pharmaceutical to boost the sales of Gan Di Xin medicine for the initial agreement term of 5 years, beginning April 22, 2021.The agreement signed through Qilian's subsidiary, Gansu Qilianshan, will see Kangzhiyuan acting as the exclusive sales agent for the distribution

Shareholder Returns

	QLI	US Pharmaceuticals	US Market
7D	6.7%	9.1%	6.6%
1Y	-54.8%	12.8%	-18.4%

Return vs Industry: QLI underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.

Return vs Market: QLI underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is QLI's price volatile compared to industry and market?
QLI volatility
QLI Average Weekly Movement	7.5%
Pharmaceuticals Industry Average Movement	11.6%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: QLI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: QLI's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2019	283	Zhanchang Xin	https://www.qlsyy.net

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications.

Qilian International Holding Group Fundamentals Summary

How do Qilian International Holding Group's earnings and revenue compare to its market cap?
QLI fundamental statistics
Market Cap	US$71.14m
Earnings (TTM)	US$3.15m
Revenue (TTM)	US$57.10m

22.6x

P/E Ratio

1.2x

P/S Ratio

Is QLI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
QLI income statement (TTM)
Revenue	US$57.10m
Cost of Revenue	US$51.46m
Gross Profit	US$5.64m
Other Expenses	US$2.49m
Earnings	US$3.15m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0.088
Gross Margin	9.87%
Net Profit Margin	5.52%
Debt/Equity Ratio	13.9%

How did QLI perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is QLI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QLI?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for QLI. This is calculated by dividing QLI's market cap by their current preferred multiple.
What is QLI's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$71.14m

QLI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	19.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does QLI's PE Ratio compare to its peers?

QLI PE Ratio vs Peers

The above table shows the PE ratio for QLI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	27.7x

Forward PE

Price-To-Earnings vs Peers: QLI is good value based on its Price-To-Earnings Ratio (22.6x) compared to the peer average (27.7x).

Price to Earnings Ratio vs Industry

How does QLI's PE Ratio compare vs other companies in the U.S. Pharmaceuticals Industry?

Price-To-Earnings vs Industry: QLI is expensive based on its Price-To-Earnings Ratio (22.6x) compared to the US Pharmaceuticals industry average (21.7x)

Price to Earnings Ratio vs Fair Ratio

What is QLI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QLI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	22.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate QLI's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of QLI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate QLI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate QLI's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QLI's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Qilian International Holding Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

8.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Qilian International Holding Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine Qilian International Holding Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Qilian International Holding Group performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-3.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: QLI has high quality earnings.

Growing Profit Margin: QLI's current net profit margins (5.5%) are lower than last year (10.1%).

Past Earnings Growth Analysis

Earnings Trend: QLI's earnings have declined by 3.9% per year over the past 5 years.

Accelerating Growth: QLI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: QLI had negative earnings growth (-37.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).

Return on Equity

High ROE: QLI's Return on Equity (5.5%) is considered low.

Discover strong past performing companies

Financial Health

How is Qilian International Holding Group's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: QLI's short term assets ($40.4M) exceed its short term liabilities ($18.2M).

Long Term Liabilities: QLI's short term assets ($40.4M) exceed its long term liabilities ($509.9K).

Debt to Equity History and Analysis

Debt Level: QLI has more cash than its total debt.

Reducing Debt: Insufficient data to determine if QLI's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: QLI's debt is not well covered by operating cash flow (4.4%).

Interest Coverage: QLI earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Dividend

What is Qilian International Holding Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate QLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QLI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as QLI has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average board tenure

CEO

Zhanchang Xin (54 yo)

no data

Tenure

US$17,939

Compensation

Mr. Zhanchang Xin has been Chairman of the Board, President and Chief Executive Officer of Qilian International Holding Group Ltd. since incorporation and served as its Acting Principal Financial Officer....

CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Zhanchang's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Zhanchang's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: QLI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/25 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2021/09/30
Annual Earnings	2021/09/30